ACR Congress Review 2019
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
etween January 2008 and December 2015. Among 10,442 patients identified, 36.5% swapped to a<br />
non-TNFi drug, most commonly abatacept (54.2%). The remaining 63.5% switched to a cycling regimen<br />
(second TNFi), most commonly adalimumab (41.2%). For subsequent lines of therapy, non-TNFi drugs<br />
were more common. Patients who swapped were significantly older and sicker than those who cycled<br />
(P
Change language